| APM | Antigen Presentation Machinery |
| B2M | β2-microglobulin |
| BiTEs | Bispecific T-cell Engagers |
| CAFs | Cancer-Associated Fibroblasts |
| CAR-T | Chimeric Antigen Receptor T cells |
| CEA | Carcinoembryonic Antigen |
| CIMP | CpG Island Methylator Phenotype |
| CRC | Colorectal Cancer |
| CTLA-4 | Cytotoxic T-Lymphocyte-Associated Protein 4 |
| ctDNA | Circulating Tumor DNA |
| DCs | Dendritic Cells |
| dMMR | Deficient Mismatch Repair |
| DNA | Deoxyribonucleic Acid |
| EGFR | Epidermal Growth Factor Receptor |
| FDA | Food and Drug Administration |
| FOLFIRI | Folinic Acid + Fluorouracil + Irinotecan |
| FOLFOX | Folinic Acid + Fluorouracil + Oxaliplatin |
| HLA | Human Leukocyte Antigen |
| ICI/ICIs | Immune Checkpoint Inhibitor(s) |
| IFN-γ | Interferon-gamma |
| ITIM | Immunoreceptor Tyrosine-based Inhibitory Motif |
| ITSM | Immunoreceptor Tyrosine-based Switch Motif |
| JAK | Janus Kinase |
| LAG-3 | Lymphocyte Activation Gene-3 |
| MAPK | Mitogen-Activated Protein Kinase |
| mCRC | Metastatic Colorectal Cancer |
| MDSCs | Myeloid-Derived Suppressor Cells |
| MHC-I | Major Histocompatibility Complex Class I |
| MHC-II | Major Histocompatibility Complex Class II |
| MLH1 | MutL Homolog 1 |
| MMR | Mismatch Repair |